Aug 12, 2020
Akero Therapeutics Reports Second Quarter 2020 Financial Results
Aug 12, 2020
Resoundant Expands Its Research Services Footprint
Aug 12, 2020
Liver Disease Diagnostics Market Size Worth $48.7 Billion By 2027: Grand View Research, Inc.
Jun 17, 2020
ASC40 (TVB-2640) Significantly Reduced Liver Fat With a 61% Responder Rate in Phase 2 NASH Trial
Jun 17, 2020
Akero Therapeutics Doses First Patient in Expansion of Phase 2a Trial in NASH
Jun 15, 2020
Data Presented at the 2020 ADA Scientific Sessions Show that Patients Treated with Cirius Therapeutics' MSDC-0602K Showed Improved Insulin Handling
Jun 15, 2020
Oramed Announces Positive Initial Clinical Trial Results for Treatment of NASH With Oral Insulin
May 26, 2020
DURECT Corporation Announces Positive Topline Data from Phase 1b Study of DUR-928 in NASH
May 13, 2020
Ascletis' THR- beta Agonist ASC41 Receives Approval for Clinical Trials of NASH Indication
May 11, 2020
DURECT Corporation Announces First Quarter 2020 Financial Results and Update of Programs
May 07, 2020
Galmed Pharmaceuticals to Report First Quarter 2020 Financial Results and Provide Business Update on Thursday May 14
Mar 31, 2020
Data on Sagimet's Lead Candidate TVB-2640 to be Presented at EASL ILC 2020
Mar 31, 2020
All AKR-001 Dose Groups Met Week 12 Efficacy Endpoints in NASH Phase 2a BALANCED Study
Mar 31, 2020
Data on NASH Candidate ASC40 to be Presented at EASL ILC 2020
Mar 25, 2020
NetNoggin® releases the exploratory analysis "NASH/NAFL 2020 Outlook"
Mar 23, 2020
Pliant Therapeutics Initiates First-in-Human Clinical Trial of PLN-1474 for the Potential Treatment of Liver Fibrosis
Mar 16, 2020
Akero Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
Mar 05, 2020
Zydus Announces World's First Drug for the Treatment of Non-Cirrhotic NASH
Mar 05, 2020
Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2019 Financial Results and Provide Business Update on Thursday March 12
Mar 03, 2020
MAX BioPharma Announces Key Update to its Liver Fibrosis Program Showing Efficacy of an Oxysterol Lead Drug Candidate in Inhibiting NASH in a Humanized Mouse Model